Cell based therapies in neurological diseases

Adriana Dulămea

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
Department of Neurology, Fundeni Clinical Institute, Bucharest, Romania

ABSTRACT

Cell therapy is a field witch has undergone tremendous expansion in recent years. A search in PubMed of the research studies on this particular subject shows an increase of up to 30,000 per year, over the past 12 years. Cell therapy is based on the idea that exogenous administration of stem cells will provide protection of the partially damaged cells and stimulate the endogenous mechanisms of tissue repair. The author presents data about characterization of stem cells, mechanisms of action and special features of mesenchymal stem cells.

Key words: mesenchimal stem cells, neuroprotection, neuroregeneration

INTRODUCTION

Translational Medicine is a new, emerging approach to the practice of medicine and to interventional epidemiology, integrating the information from fundamental research studies, as well as from social and political sciences, in order to optimize therapy and disease prevention methods. The process aims at transforming the discoveries made through groundbreaking research into drug therapies or medical tools. This new medical field makes the connection among experimental studies, clinical trials and clinical practice.

Generally, in adult pathological conditions that involve cell destruction or inflammation, adult stem cells, which are present latently throughout life, are stimulated to multiply, differentiate and migrate to the damaged tissue or organ, where they secrete trophic, anti-inflammatory factors or factors involved in immunomodulation and immunosuppression and where they can even differentiate into cells of the damaged tissue.

However, the intervention of stem cells is insufficient to stop pathological processes and to trigger the regeneration of the damaged tissues. For this reason, researchers have attempted to develop, on animal models of various diseases, regenerative cell therapies based on the external input of stem cells or of cells derived therefrom, that complement and stimulate the body’s natural response.
There are numerous ongoing clinical studies conducted for the purpose of evaluating the safety and efficiency of therapies using adult stem cells, particularly stem cells from hematogenous bone marrow and mesenchymal stem cells from adipose tissue, embryonic stem cells, fetal and umbilical cord cells, for a wide variety of pathological processes specific to neurodegenerative, autoimmune, genetic diseases, in traumatic brain or spinal injuries, for neural regeneration after stroke, as delivery vectors for gene therapy in invasive brain tumors in idiopathic epilepsies, as well as in muscle diseases and peripheral neuropathies.

**Characterization of stem cells**

Stem cells are different from other precursor cells by two specific features. Firstly, they are self-renewing, possessing the capacity to proliferate and to reproduce indefinitely. Secondly, they are multi- or pluripotent, meaning that they are able to differentiate into multiple cell types. These processes are regulated by the microenvironment in which they live.

**Cell therapy in neurological diseases**

There are already numerous preclinical studies on experimental models of neurological pathology and clinical trials, either ongoing or completed, which have revealed the features and action mechanisms of different types of stem cell populations in immunomodulation, the induced neuroprotection and neurogenesis, thus showing the capabilities of these cells in neuroregeneration and neuroplasticity.

The stem cell populations used in neurological diseases were very diverse. Embryonic stem cells (ESC) which represent the stem cell prototype have an extremely high capacity to transdifferentiate 1], but their transplantation is associated with a high risk of carcinogenesis 2]. The somatic stem cells used in the process were neural stem cells (NSC) 3. a n d mesenchymal stem cells (MSC) 4. which are relatively easy to harvest from different adult tissues and can be expanded in vitro. NSC-s have the advantage of being naturally "neuralized", but involve many scientific, legal and ethical limitations regarding their harvesting and transplantation into an adult brain 5]. Another disadvantage is that after extended culture they tend to assume a glial cell pattern that diminishes their therapeutic potential.

Mesenchymal stem cells (MSC) are a heterogeneous population of stromal cells isolated from hematogenous bone marrow and tissues derived from mesoderm: adipose tissue, pleural cavity, lymph node, muscle, teeth.

In 2006, the International Society for Cellular Therapy (ISCT) proposed minimum criteria to define human MSC 6]:

1. MSCs must be adherent to plastic when maintained in standard culture conditions;
2. MSCs must express CD105, CD73 and CD90 and they must lack expression of CD34, CD45, CD14 or CD11b, CD79a, CD19 and HLADR surface molecules;
3. MSCs must differentiate in vitro into osteoblasts, chondroblasts and adipocytes.

MSCs from the bone marrow (BM) or BM non-hematopoietic stem cells contribute to the formation of hematopoietic stem cells (HSC) niche that support hematopoiesis 7. and maintain HSCs in a quiescent state exhibiting an anti-proliferative activity 8,9.

Within the bone marrow, MSCs are rare (approximately 1 in 10,000 cells) and can be isolated from other BM cells by their potency to adhere to tissue culture plastic; these cells have a spindle-shaped fibroblast-like morphology and can be expanded and enriched through culturing for 3–5 weeks 10, 11.

MSCs have many advantages: they are easy to harvest, can be quickly isolated, expanded and stored for a period of time, can be administered in various ways, are relatively immune-privileged and do not require immunosuppression even with allogeneic transplantation, they may be administered through different methods, have similar efficiency as neural stem cells, a good safety profile and do not raise ethical controversy.

**The mechanism of action and features of MSC**

MSC show therapeutic potential for neurological and central nervous system lesions due to their mechanism of action and their unique properties: immunomodulation capacity, neuroprotection, neuroregeneration and neurogenesis 12]. If administered intravenously MSC migrate into lymphoid peripheral organs, which induces peripheral tolerance to T cells by modulating the innate and adaptive immunity because their action on B, T and NK cells 13-17]. Most MSC are captured in the lungs where they induce regulation through cytokines involved in suppressing the inflammation, possibly by interacting with local cells such as macrophages. Numerous in vitro studies have shown that MSC migrate and cross the blood-brain lesions, being attracted to the central nervous system (CNS), a phenomenon called "homing" 18-20].

This mechanism is mediated especially by inflammatory chemokines concentrated at the site of inflamma-
Migratory features of MSCs and "homing"

There are numerous in vitro and in vivo studies showing the potential of MSCs to migrate and engraft after intravenous administration or brain transplantation and the ability to survive in the microenvironment of nervous tissue. In healthy animals the majority of transplanted MSCs trafficked to lymph nodes, lungs and spleen but in EAE animal models MSCs are attracted to sites of lesion. Similar to immune cells, MSCs can extravasate from the blood vessels as a result of the expression of adhesion molecules on their surface. MSCs show coordinated rolling and adhesion behaviour on endothelial cells in a p-selectin- and vascular cell-adhesion molecule 1 (vCAM1)-dependent manner. MSCs migrate in response to several chemokines that bind to cognate receptors expressed on their cell surface and lead to the activation of matrix metalloproteinases that degrade the basement membrane and allow subsequent extravasation.

The experiments of Jackson and coworkers showed that systemically administered MSCs seem to preferentially home to the site of injury, where they support functional recovery.

Tyukavin and colleagues showed that activation of apoptosis is a potent physiological stimulus for targeted migration of MSCs from the blood to tissues.

Karp M and Leng Teo GS (2009) discussed in...
their review the issues regarding tracking and efficacy of homing to the inflammation sites in CNS for exogenously delivered MSCs and also if host MSCs can be mobilized into peripheral blood and then target the lesions.

He Q. and coworkers 46. reviewed the studies about peripheral blood MSCs and the factors and conditions that promote their mobilization into the peripheral blood.

Taken together, these studies suggest that the clinical and pathological benefit appeared to be mediated by inhibition of peripheral encephalitogenic T-cells. However, several lines of evidence from animal studies suggest the beneficial effects of MSCs in EAE also may reflect a more direct influence of MSCs on neural cell responses to inflammatory CNS injury 47].

Paracrine effect conducive of neuroprotection and neuroregeneration

It has been showed on animal models of EAE that exogenous MSCs induce enhancement of endogenous repair processes through a "bystander activation" mechanism mediated by the production of multiple growth factors.

The secretion of varied neurotrophic factors such as: brain-derived neurotrophic factors (BDNF) 48], nerve growth factor (NGF) 49], insulin-like growth factor-1 (IGF-1) 50], glial derived neurotrophic factor (GDNF) 51] is responsible for the neuroprotective effects and for neuroregeneration.

Through the release of trophic and anti-apoptotic molecules, MSCs rescues neurons and oligodendrocytes from apoptosis and can have anti-inflammatory and anti-proliferative effects on microglial cells and astrocytes, thus creating a neuroprotective microenvironment.

In addition, MSCs can promote the proliferation and maturation of local neural precursor cells, leading to their differentiation into mature neurons and oligodendrocytes.

MSC initiates the same endogenous repair through the same "by-stander activation" mechanism, as they induce proliferation, maturation and differentiation of neuronal local precursors into mature neurons, thus leading to a certain degree of neuronogenesis.

MSCs migrate into the CNS where they promote BDNF production and induce proliferation of a limited number of oligodendrocyte progenitors in oligodendrocytes, helping oligodendrogenesis, which enhances remyelination and improves axonal integrity in lesions 52].

Neuronal differentiation

Studies were carried out involving cancer patients who received intravenous injection of bromodeoxyuridine in order to map out the neuronal division. In these patients CNS was studied after death and the findings are that new neurons are continuously generated 53]. It is the current view that, under normal condition, stem cells from a normal brain can permanently renew themselves and have a pluripotent capacity to differentiate into many cells 54-57]. Although the human brain stem cells are capable capacity of continuous renewal, it is not known why these cells show reduced ability to proliferate and differentiate into neurons when it is necessary to repair a CNS injury.

In order to recognize MSC differentiation into neuron-like cells certain morphologic parameters and phenotypic changes need to be evaluated 58-61]. Some studies described MSC differentiation into cells with extensions similar to neuronal extesions hours after treating MSC with certain chemical substances 62], while other studies reported MSC transdifferentiation into neuronal phenotypes or functional neurons which had functional synaptic transmission, in the context of a specific induction 63]. Zeng and his coworkers 64. studied the BM-MSC capacity to differentiate into neuron-like cells in vitro, in various conditions and concluded that these cells have great potential to differentiate into functional neurons. The presence of VEGF, BDNF or of 2% dimethyl sulfoxide in MSC culture can stimulate these cells to develop neuronal morphology and to start expressing neuronal markers 65,66. However, it remains unclear whether this phenomenon reflects transdifferentiation, ectopic expression of markers or cell fusion. In studies with labeled MSC limited data were obtained concerning the transformation of transplanted MSC into functional neuronal cells.

There is much controversy in the scientific community regarding the neuronal differentiation of MSC. The reasons are as follows:

1. the ability of MSC to differentiate into cells of all three germ layers must be carefully considered because there are studies that reported the ability of MSC to express spontaneous neuronal markers, even in the undifferentiated state. If we assume that there is neuronal differentiation, it is not clear what factors determine the molecular profile of MSC differentiation after transplantation.
2. neuron-like cells in which MSC differentiate are not functional neurons, but cells with pseudo-
neuronal morphology caused by chemical induction 67-70].

3. there is no correlation between the number of MSC and functional recovery, which means that neurological recovery can be determined not by the differentiation of MSC, but by the mediators secreted by MSC which limit cell death and stimulate the proliferation of progenitor cells 71,72].

4. MSC differentiation into neuronal phenotypes was mainly the result of the donor MSC merging with the host cells, which led to the false immunopositive results at characterization time 73].

**Angiogenesis**

Research has shown that MSCs from bone marrow are able to remodel vascularization by increasing the synthesis of numerous cytokines, including IL-6, IL-7 and VEGF 74-79].

**Axonal sprouting**

MSC provides a conducive environment for axonal regeneration, axonal guidance, neuronal cells migration, degradation of glial scars through matrix metalloproteinases (MMPs) and bypasses lesions by synthesis of certain matrix components permissive for neurons inside the lesions, which helps reduce cavitation in the damaged tissue and raises the possibility of interneuronal interaction 26,80-83].

**Experimental studies and clinical experience with mesenchymal stem cell therapy**

Clinical experience with mesenchymal stem cell therapy is represented by pilot studies, open-labeled studies, several non-randomized studies and randomized studies.

In a recent paper, Karussis and his colleagues 84. conducted an analysis and synthesis of these studies and highlighted the following: the allogeneic transplant using stem cells from donor seems to have a higher potential to achieve neural repair, because the transplanted stem cells do not have the genetic defects involved in the pathogenesis of the neurological disease. Donor stem cells can also operate as the vehicle for transfer of normal gene in neurogenetic syndromes. Apart from some small studies which used MSC from bone marrow, the literature data are very limited in terms of allogeneic transplantation. In a pioneering study 85. in which allogeneic MSC infusion was used in patients with Hurler syndrome (mucopolysaccharidosis type IH) or metachromatic leukodystrophy, no toxic effects were found and, although the clinical state of the patients was stable, an improvement in the nerve conduction velocity was recorded.

The main disadvantage of allogeneic transplantation is the risk of rejection of transplanted 86. cells and the potential need for immunosuppressive therapy in order to improve the cells' long-term viability. This problem seems to be less striking in embryonic stem cells because these type of cells seem to be immune-privileged 87,88]. Most clinical data result from clinical trials involving autologous stem cells.

A clinical research study with MSC recorded on www.clinicaltrial.gov highlights a number of 310 clinical trials out of which 48 for neurological diseases: multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, cerebellar ataxia, brain stroke, head and spinal trauma, Duchenne muscular dystrophy and other diseases.

A systematic review and meta-analysis of clinical trials with MSC 89. including 36 studies and 1012 participants did not detect an association between acute infusional toxicity, organ system complications, infection, death or malignancy. However there was a significant association between MSC and transient fever. Based on the current clinical trials, MSC therapy appears safe, still further larger scale controlled clinical trials with rigorous reporting adverse events are required to further define the safety profile of MSC.

**REFERENCES**


11. Dimitrios Karussis, Ibrahim Kassis, Basan Gowda S. Kurkalli, Shimon...


28. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Human mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006;107: 1484–90


Adriana Dulámea


